When the National Agency for Food and Drug Administration and Control (NAFDAC) announced that imports of selected essential medicines had dropped by 70%, most observers treated it as a routine healthcare headline.
They noted the increase in domestic pharmaceutical manufacturing facilities from 174 to 190 and the surge in contract manufacturing entities from 10 to 87 since 2019, then moved on.
They may be missing the bigger picture.
For macroeconomic analysts, industrial policy planners, and private investors, these figures represent more than a win for public health regulation. They signal an industrial turning point that capital markets and corporate decision-makers may not yet be pricing correctly.
For decades, local pharmaceutical manufacturing in West Africa was largely viewed as a conversation about “potential”—an ambition repeatedly undermined by foreign exchange volatility, cheap imports, and structural infrastructure deficits.
That narrative is now beginning to change.
A Shift in Nigeria’s Pharmaceutical Landscape
Driven by NAFDAC’s aggressive 5+5 policy, an expanded “Ceiling List” restricting targeted imported formulations, and a recent Presidential Executive Order granting zero tariffs and VAT on pharmaceutical machinery and raw materials, the balance between imported and locally manufactured medicines in Nigeria has shifted from a historical 70:30 ratio to roughly 50:50.
Dozens of facilities are currently under construction or undergoing compliance upgrades.
More significantly, global industry players are beginning to take notice. German multinational Bayer recently finalised a landmark technology-transfer agreement to manufacture reproductive health commodities locally in Anambra State.
Taken together, these developments point to a fundamental reconfiguration of West Africa’s pharmaceutical supply chain, with significant implications for domestic health security, high-skilled job creation, investment, and industrial technology transfer.
But as market forces and government policy increasingly align, a critical strategic question emerges:
Are we simply building more pharmaceutical factories, or are we building a sustainable pharmaceutical manufacturing ecosystem?
The distinction is crucial.
Beyond Building More Factories
More factories give a country additional industrial capacity.
A manufacturing ecosystem, however, provides those factories with the structural tools required to remain competitive without relying indefinitely on policy protection.
That ecosystem requires stable high-voltage power, domestic active pharmaceutical ingredient (API) production, access to long-term competitive capital, streamlined customs clearance, and efficient export infrastructure.
Import restrictions and executive orders can temporarily create room for domestic producers to expand. But tariff walls alone cannot reduce the unit cost of producing a blister pack.
A facility that depends heavily on diesel-powered generation, imports 99% of its raw chemical inputs in foreign currency, and operates in isolation faces an inherent cost disadvantage.
If policy protections were removed tomorrow, such a facility could struggle to compete with high-volume, low-cost producers in countries such as India and China.
This is where regional competition within Sub-Saharan Africa becomes increasingly important.
The Regional Race
Ghana is pursuing the ecosystem model through its proposed 2,000-acre pharmaceutical park, designed to centralise industrial effluent treatment, power infrastructure, and customs processing.
Rwanda, meanwhile, is positioning itself as a regional biotechnology gateway by streamlining regulatory approvals under WHO maturity frameworks and establishing specialised cold-chain logistics hubs.
Nigeria has advantages that neither neighbour can easily match.
The country has Africa’s largest addressable patient market, a deep pool of clinical and engineering talent, and strong political momentum behind local pharmaceutical production.
However, domestic scale alone does not guarantee regional dominance, particularly under the African Continental Free Trade Area (AfCFTA).
To transform forced import substitution into sustainable global competitiveness, Nigeria must move beyond simply increasing the number of manufacturing facilities.
Three Priorities for a Sustainable Pharmaceutical Ecosystem
A coordinated effort involving the Federal Ministry of Health and Social Welfare, the Ministry of Industry, Trade and Investment, and private financial institutions should focus on three immediate priorities.
1. Build Aggregated Infrastructure
Rather than scattering pharmaceutical facilities across isolated locations, industrial policy should incentivise spatial clustering through specialised pharmaceutical industrial parks.
Shared infrastructure—including water purification systems, heavy industrial power-grid connections, waste-treatment facilities, and other utilities—could significantly reduce operating costs and improve efficiency.
2. Move Upstream Into APIs and Excipients
Localising the production of finished tablets and medicines while continuing to import active pharmaceutical ingredients merely shifts Nigeria’s foreign-exchange vulnerability further upstream.
Nigeria should leverage its expanding refining and petrochemical capacity to develop local production of basic excipients, solvents, and key starting materials (KSMs).
Building this upstream capacity would reduce dependence on imported inputs and strengthen the resilience of the entire pharmaceutical value chain.
3. Harmonise Regulatory Standards for Export
NAFDAC’s push towards WHO Maturity Level 4 certification must be matched by practical support for domestic manufacturers seeking WHO prequalification.
Achieving internationally recognised regulatory standards would allow Nigerian pharmaceutical companies to access institutional procurement opportunities and compete more effectively for exports across AfCFTA member states.
From Protection to Competitiveness
Protective policy can create the breathing room domestic industries need to take root.
But industrial competitiveness is what ensures they survive and prosper.
Nigeria has been presented with a rare opportunity to transition from being Africa’s largest consumer of imported medicines to becoming one of the continent’s leading pharmaceutical manufacturing hubs.
The policy-driven demand shock has arrived, and the factories are going up.
The remaining question is whether Nigeria’s public and private sectors can build the underlying ecosystem quickly enough to make these businesses competitive—not just today, but for generations to come.
